were searched for the following terms: "tenofovir", "hepatitis B", and "pregnancy" from inception of each database until August 2018. No language restrictions were applied. We included all prospective comparative trials of tenofovir administration vs. controls for pregnant patients with chronic hepatitis B infection assessing mother to child transmission rates. The primary outcome was newborn HBsAg positivity at 6-9 Months. Meta-analysis was performed using a random effects model to produce summary treatment effects in terms of odds ratio, with 95% confidence intervals. Heterogeneity was measured using Chi-square and I 2 statistics. The quality of the evidence was assessed using the Cochrane Risk of Bias assessment tool. Data analysis was conducted with Review Manager v. 5.3. RESULTS: Five studies (two randomized controlled trials, three nonrandomized controlled trials) that enrolled 813 women were included. The results from comparative trials showed that maternal treatment with tenofovir did not significantly reduced the risk of infant hepatitis B surface antigen seropositivity between 6-9 months of age (odds ratio ¼ 0.39, 95% confidence intervals ¼ 0.10, 1.50, P ¼ 0.17) I2 44%. CONCLUSION: For pregnant women with hepatitis B virus, tenofovir administration did not prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Further well-designed RCTs are necessary to confirm the findings of this study. OBJECTIVE: Acute funisitis (AF) has been shown to be part of the fetal inflammatory response seen in association with acute chorioamnionitis (AC) and ascending infection. However, the significance of AF seen in isolation is not known. The objective of this study was to evaluate clinical and pathologic features of cases of isolated AF in order to determine the significance of this finding and how it can contribute to our understanding of adverse clinical outcomes. STUDY DESIGN: This was a retrospective review of third trimester placentas of patients who delivered at our institution from 1997-2017. Our institution's surgical pathology database was searched for third trimester placentas with the diagnosis of AF without a diagnosis of AC. Placentas without AF or AC were controls and placentas with AF but without AC were cases. RESULTS: There were 156 cases and 183 controls identified. Maternal age, gestational age, birthweight, mode of delivery and Apgar scores were similar in both groups. There was no increase in histologic lesions associated with maternal vascular malperfusion, fetal vascular malperfusion, cord complications or chronic villitis. In the cases, 132 (84.6%) of had meconium in fetal membranes, and of those, 70 (44.9%) also had meconium in the umbilical cord. 34(21.8%) of those with meconium in the umbilical cord also had myonecrosis. In the controls, 72(39.3%) had meconium in fetal membranes, and of those, 8(5.1%) also had meconium in the umbilical cord. 5(2.8%) of those with meconium in the umbilical cord also had myonecrosis. When comparing the presence of meconium in the membranes, meconium in the cord and myonecrosis in the cases and controls, all comparisons were found to be significant (84.6% vs 39.3%, p¼<.00001, 44.9% vs 5.1%, p ¼ <.0001 and 21.8% vs 2.75%, p ¼<.00001, respectively). CONCLUSION: AF can be indicative of placental abnormalities other than AC. There is a strong association between AF without AC and the presence of meconium, particularly in the umbilical cord. As meconium can be associated with myonecrosis of umbilical vessels, in some cases AF may be the result of damage to the muscle fibers of the cord rather than an ascending infection.
657 Improving the prediction of shoulder dystocia using artificial intelligence e a novel approach to 2018 from a large tertiary university-affiliated hospital was analyzed. All ShD cases during the study period were identified, and comprehensive prenatal, obstetric and neonatal data from ShD cases were compared with 4:1 controls of singleton vaginal deliveries from the same institution. The AI model incorporated maternal factors (age, height, weight at delivery, smoking, diabetes, insulin treatment), obstetric history (parity, prior CS and prior ShD), fetal sonographic parameters within 2 wks of delivery (BPD, AC, HC, FL, and EFW) and neonatal factors (birth weight and sex). To develop a ShD prediction model, we split the data to training and test sets (80%-20%), and fit a generalized linear model with Lasso regularization on the training set. We repeated the learning with 100 random splits of the data. RESULTS: 239 (0.44%) cases of ShD occurred during the study period. The mean newborn weight among ShD cases was significantly higher than controls (3857g vs 3230g respectively, P < 0.01); however, there was a wide overlap between groups (Fig 1) . The AI model identified 12 variables to include in the prediction of ShD with different predictive strengths, some of them protective (Fig 2) . Incorporating all factors, the model was able to prevent 41.7% of ShD cases using a 10% elective CS rate cutoff. This CS rate is equivalent to a universal 4000g elective CS recommendation, 
